ARWRArrowhead Pharmaceuticals, Inc.
$62.78+105% 1Y
$62.78
$31.6652 weeks$89.61
ARWR in its own filings
ARWR's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
453
Events found in the filings · across 1,359 filings · the record starts in 1998
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 7, 1998
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 24, 2026
- Change in certifying accountantpast_3y
- 2023-12-05
- Late periodic report7 occurrences
- 2003-12-29
- Delisting notice / listing-rule failure8 occurrences
- 2011-11-15
- Material impairmenthistorical
- 2005-06-09
- SEC comment-letter activity66 occurrences
- 2023-05-19
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results.Earnings release · press release
- Jun 16, 2026Appointment of Dr. Matt Cohen as a Director On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.Director or officer change · Form 8-K
- May 7, 2026Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results.Earnings release · press release
- Feb 5, 2026Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results.Earnings release · press release
- Jan 12, 2026Indenture and Notes On January 12, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) issued $700,000,000 aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”)Material agreement entered · Form 8-K
- Jan 9, 2026Equity Offering On January 7, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (collectively, the “Equity Underwriters”), to …Material agreement entered · Form 8-K
- Jan 6, 2026On January 6, 2026, the Company announced interim results from its Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7.Regulation FD disclosure · Form 8-K
- Nov 25, 2025Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results.Earnings release · press release
- Nov 18, 2025On November 18, 2025, Arro whead Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved REDEMPLO ® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)Other event · Form 8-K
- Sep 12, 2025Arrowhead Pharmaceuticals, Inc. (the “Company”) was notified that on September 11, 2025, Ionis Pharmaceuticals, Inc. (“Ionis”) filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of United States Patent …Other event · Form 8-K
- Sep 11, 2025On September 10, 2025, Arrowhead Pharmaceuticals, Inc. (the “Company” or the “Plaintiff”) filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (the “Defendant”) to declare that Ionis’s United States Patent Number 9,593,333 (“the …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…